Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2007.14.5367 on February 19 2008

Journal of Clinical Oncology, Vol 26, No 9 (March 20), 2008: pp. 1544-1552
© 2008 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chanan-Khan, A. A.
Right arrow Articles by Cheson, B. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chanan-Khan, A. A.
Right arrow Articles by Cheson, B. D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

REVIEW ARTICLE

Lenalidomide for the Treatment of B-Cell Malignancies

Asher A. Chanan-Khan, Bruce D. Cheson

From the Roswell Park Cancer Institute, Buffalo, NY; and Georgetown University Hospital, Washington, DC

Corresponding author: Asher A. Chanan-Khan, MD, Elm & Carlton St, Buffalo, NY 14263; e-mail: asher.chanan-khan{at}roswellpark.org

Lenalidomide is a novel anticancer agent that has made a major impact in the treatment of patients with B-cell malignancies. A more potent analog of thalidomide, lenalidomide was developed to enhance immunomodulatory properties with improved safety profile. Its antitumor activity seems mediated through modulation of both the cytokine and cellular tumor cell microenvironment. Preclinical as well as clinical observations demonstrate that lenalidomide downregulates production of various critical prosurvival cytokines in the tumor microenvironment while concurrently promoting activation of T- and natural killer (NK) cell-mediated antitumor response. Early clinical investigations noted its efficacy in relapsed and/or refractory multiple myeloma patients. Subsequently, larger randomized studies confirmed the clinical benefit of lenalidomide when added to dexamethasone compared with dexamethasone alone in previously treated myeloma patients resulting in its recent approval by the US Food and Drug Administration. Consequently, the role of lenalidomide in other B-cell malignancies has been investigated, with impressive results in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. This review summarizes the data from various clinical investigations and highlights the impact of lenalidomide in the management of patients with B-cell malignancies.

published online ahead of print at www.jco.org on February 19, 2008.

Supported in part by the Jerra Barit Myeloma Research Fund (A.C.-K.).

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
BloodHome page
A. G. Ramsay, A. J. Clear, G. Kelly, R. Fatah, J. Matthews, F. MacDougall, T. A. Lister, A. M. Lee, M. Calaminici, and J. G. Gribben
Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy
Blood, November 19, 2009; 114(21): 4713 - 4720.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. E. Witzig, P. H. Wiernik, T. Moore, C. Reeder, C. Cole, G. Justice, H. Kaplan, M. Voralia, D. Pietronigro, K. Takeshita, et al.
Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
J. Clin. Oncol., November 10, 2009; 27(32): 5404 - 5409.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
A. G. Ramsay and J. G. Gribben
Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug
Haematologica, September 1, 2009; 94(9): 1198 - 1202.
[Full Text] [PDF]


Home page
haematolHome page
G. Aue, N. Njuguna, X. Tian, S. Soto, T. Hughes, B. Vire, K. Keyvanfar, F. Gibellini, J. Valdez, C. Boss, et al.
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia
Haematologica, September 1, 2009; 94(9): 1266 - 1273.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Xu, J. Li, G. D. Ferguson, F. Mercurio, G. Khambatta, L. Morrison, A. Lopez-Girona, L. G. Corral, D. R. Webb, B. L. Bennett, et al.
Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases
Blood, July 9, 2009; 114(2): 338 - 345.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
W. L. Dahut, J. B. Aragon-Ching, S. Woo, T. M. Tohnya, J. L. Gulley, P. M. Arlen, J. J. Wright, J. Ventiz, and W. D. Figg
Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer
J. Clin. Pharmacol., June 1, 2009; 49(6): 650 - 660.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
A. Delmonte, M. Ghielmini, and C. Sessa
Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin's Lymphomas
Oncologist, May 1, 2009; 14(5): 511 - 525.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Morel, A. Duhamel, P. Gobbi, M. A. Dimopoulos, M. V. Dhodapkar, J. McCoy, J. Crowley, E. M. Ocio, R. Garcia-Sanz, S. P. Treon, et al.
International prognostic scoring system for Waldenstrom macroglobulinemia
Blood, April 30, 2009; 113(18): 4163 - 4170.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
L. Maggio-Price, P. Treuting, H. Bielefeldt-Ohmann, A. Seamons, R. Drivdahl, W. Zeng, L. Lai, M. Huycke, S. Phelps, T. Brabb, et al.
Bacterial Infection of Smad3/Rag2 Double-Null Mice with Transforming Growth Factor-{beta} Dysregulation as a Model for Studying Inflammation-Associated Colon Cancer
Am. J. Pathol., January 1, 2009; 174(1): 317 - 329.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online